Results 51 to 60 of about 31,178 (269)
Advances in preclinical and clinical studies of oncolytic virus combination therapy
Frontiers in OncologyOncolytic viruses represent a distinct class of viruses that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic viruses encounter several challenges as standalone therapies.
Wenlong Du +4 more
doaj +1 more source
MedComm – Oncology, 2023 The most deadly and aggressive form of brain cancer is called a glioblastoma multiforme. Following diagnosis, the median duration of survival is only 14 months.
Tanvir Ahmed
doaj +1 more source
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Mesenchymal stem cells as vectors for lung cancer therapy [PDF]
, 2013 Despite recent advances in treatment, lung cancer accounts for one third of all cancer-related deaths, underlining the need of development of new therapies.
Janes, SM, Kolluri, KK, Laurent, GJ
core +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
Advanced Science, EarlyView.T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases
Advanced Science, EarlyView.This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo +5 more
wiley +1 more source
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
Viruses, 2015 Oncolytic viruses represent a diverse class of replication competent viruses that curtail tumor growth. These viruses, through their natural ability or through genetic modifications, can selectively replicate within tumor cells and induce cell death ...
Karishma R. Rajani, Richard G. Vile
doaj +1 more source
Current strategies in engaging oncolytic viruses with antitumor immunity
Molecular Therapy: Oncolytics, 2021 Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni +2 more
doaj +1 more source
Advanced Science, EarlyView.Tumor vascular remodeling is discussed from a chemokine‐centered perspective. This review summarizes the bidirectional, temporal, and tissue‐specific roles of CXC chemokines in regulating vascular function and immune accessibility. A functional vascular normalization score is introduced as a conceptual framework to integrate dynamic vascular and immune
Hongdan Chen +7 more
wiley +1 more source
Fusogenic Viruses in Oncolytic Immunotherapy [PDF]
Cancers, 2018 Oncolytic viruses are under intense development and have earned their place among the novel class of cancer immunotherapeutics that are changing the face of cancer therapy. Their ability to specifically infect and efficiently kill tumor cells, while breaking immune tolerance and mediating immune responses directed against the tumor, make oncolytic ...
Teresa Krabbe, Jennifer Altomonte
openaire +3 more sources